USRE39706E1 - Crystalline form of a vitamin D analogue - Google Patents

Crystalline form of a vitamin D analogue Download PDF

Info

Publication number
USRE39706E1
USRE39706E1 US10/986,575 US98657593A USRE39706E US RE39706 E1 USRE39706 E1 US RE39706E1 US 98657593 A US98657593 A US 98657593A US RE39706 E USRE39706 E US RE39706E
Authority
US
United States
Prior art keywords
calcipotriol
pharmaceutical composition
monohydrate
hydrate
calcipotriol monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/986,575
Inventor
Erik Torngaard Hansen
Niels Smidt Rastrup Andersen
Lene Hoffmeyer Ringborg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10728784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE39706(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of USRE39706E1 publication Critical patent/USRE39706E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/02—Apparatus characterised by being constructed of material selected for its chemically-resistant properties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/321—Catalytic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/327—Formation of non-aromatic carbon-to-carbon double bonds only
    • C07C5/333—Catalytic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/32—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
    • C07C5/327—Formation of non-aromatic carbon-to-carbon double bonds only
    • C07C5/333—Catalytic processes
    • C07C5/3335—Catalytic processes with metals
    • C07C5/3337—Catalytic processes with metals of the platinum group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/0204—Apparatus characterised by their chemically-resistant properties comprising coatings on the surfaces in direct contact with the reactive components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/0204—Apparatus characterised by their chemically-resistant properties comprising coatings on the surfaces in direct contact with the reactive components
    • B01J2219/0236—Metal based
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/02—Apparatus characterised by their chemically-resistant properties
    • B01J2219/025—Apparatus characterised by their chemically-resistant properties characterised by the construction materials of the reactor vessel proper
    • B01J2219/0277—Metal based
    • B01J2219/0286—Steel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
    • C07C2523/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals
    • C07C2523/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals of the platinum group metals
    • C07C2523/42—Platinum

Definitions

  • the present invention relates to calcipotriol, hydrate—a new crystalline form of calcipotriol—with superior technical properties e.g. in the manufacture of crystal suspension formulations, and with superior stability properties.
  • Calcipotriol (INN) (calcipotriene (USAN), (1 ⁇ ,3 ⁇ ,5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19), 22-tetraene-1,3,24-triol) is described in International patent application No. PCT/DK86/00081, filing date 14th Jul. 1986, publication No. WO 87/00834.
  • Calcipotriol possesses a remarkable profile of biological activity which has proved very useful e.g. in the topical treatment of psoriasis.
  • crystalline bulk drug is usually subjected to micronization or to a wet milling process in order to reduce the crystal size before the final suspension formulation is prepared.
  • This novel product is the monohydrate of calcipotriol which is perfectly crystalline, stable and wet suited for its use in modern therapy.
  • the anhydrous form of calcipotriol shows a considerable degree of decomposition at this temperature and more than 30% degradation is seen after 12 months storage.
  • Calcipotriol monohydrate may be prepared by dissolving crystalline or non-crystalline calcipotriol in an organic solvent, e.g. ethyl acetate or acetone, followed by the addition of water and optionally a non polar solvent, e.g. hexane.
  • organic solvent e.g. ethyl acetate or acetone
  • non polar solvent e.g. hexane.
  • Calcipotriol monohydrate shall form part of pharmaceutical preparations for topical use, such as creams, ointments, solutions, lotions or gels.
  • concentration of the active ingredient will generally be between 1 and 100 ⁇ g/g.
  • the formulations will be applied one or more times daily.
  • the formulations prepared according to the present invention comprise the active compound in association with a pharmaceutically acceptable vehicle and optionally other therapeutic ingredient(s).
  • vehicle(s) must be “acceptable” in the sense of being compatible with the other ingredients of the preparations and not deleterious to the recipient thereof.
  • Preparations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments, pastes or gels; or solutions or suspensions.
  • the preparations of this invention may include one or more additional ingredients such as diluents, buffers, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.
  • additional ingredients such as diluents, buffers, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.
  • Calcipotriol (2.5 g) was dissolved in ethyl acetate (80 ml) at 50°-80° C. and filtered. The solution was saturated with water, and the product precipitated upon voluntary cooling to room temperature. The resulting slurry was cooled to 0°-10° C. and filtered. The filtered product was dried in vacuo to give calcipotriol, hydrate (2.35 g).
  • Lines characteristic for the hydrate are 1455 (m), 1442 (m), 1330 (w), 1290 (m), 1210 (m), 1085 (m), 907 (m), 895 (m) and 573 (w) cm ⁇ 1 , respectively.
  • Solid state CPMAS 1 CPMAS 13 C NMR The following resonances are characteristic for calcipotriol, hydrate: 147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2 and 1.9 ppm, respectively.

Abstract

The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.

Description

This application is a 371 of PCT/DK94/00011 filed Jan. 7, 1994.
The present invention relates to calcipotriol, hydrate—a new crystalline form of calcipotriol—with superior technical properties e.g. in the manufacture of crystal suspension formulations, and with superior stability properties.
Calcipotriol (INN) (calcipotriene (USAN), (1α,3β,5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19), 22-tetraene-1,3,24-triol) is described in International patent application No. PCT/DK86/00081, filing date 14th Jul. 1986, publication No. WO 87/00834.
Calcipotriol possesses a remarkable profile of biological activity which has proved very useful e.g. in the topical treatment of psoriasis.
Due to the poor stability of calcipotriol in certain solutions it is in some formulations, in particular in creams and gels, preferred to use crystal suspensions.
In order to prepare suitable crystal suspension formulations it is mandatory to be able to control the crystal size, this parameter being important with regard to obtaining a reproducible release of the active compound from the formulation. The crystalline bulk drug is usually subjected to micronization or to a wet milling process in order to reduce the crystal size before the final suspension formulation is prepared.
In the case of calcipotriol a wet ball milling process has been used. However, it has turned out to be technically difficult to perform this process when using the anhydrous crystal form described in WO 87/00834. These crystals are not easily wetted and during the milling process they develop a stable foam which results in difficulties in obtaining a suitable small and uniform particle size.
It has now surprisingly been found that these technical problems can be avoided when a hitherto unknown crystalline form of calcipotriol, i.e. calcipotriol, hydrate, is used instead of the known anhydrous form. The hydrate is technically superior to the anhydrate; it is easily wetted and the wet ball milling process is running smoothly.
This novel product is the monohydrate of calcipotriol which is perfectly crystalline, stable and wet suited for its use in modern therapy.
Stability studies have demonstrated that calcipotriol, hydrate is surprisingly stable, and this is illustrated by stability data at 40° C.
The anhydrous form of calcipotriol shows a considerable degree of decomposition at this temperature and more than 30% degradation is seen after 12 months storage.
In contrast the compound of the present invention, calcipotriol hydrate, shows no degradation after 12 months storage at 40° C.
Calcipotriol, monohydrate may be prepared by dissolving crystalline or non-crystalline calcipotriol in an organic solvent, e.g. ethyl acetate or acetone, followed by the addition of water and optionally a non polar solvent, e.g. hexane.
Calcipotriol, monohydrate shall form part of pharmaceutical preparations for topical use, such as creams, ointments, solutions, lotions or gels. The concentration of the active ingredient will generally be between 1 and 100 μg/g.
The formulations will be applied one or more times daily.
The formulations prepared according to the present invention comprise the active compound in association with a pharmaceutically acceptable vehicle and optionally other therapeutic ingredient(s). The vehicle(s) must be “acceptable” in the sense of being compatible with the other ingredients of the preparations and not deleterious to the recipient thereof.
Preparations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments, pastes or gels; or solutions or suspensions.
In addition to the aforementioned ingredients, the preparations of this invention may include one or more additional ingredients such as diluents, buffers, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.
The invention will now be further described in the following non-limiting Examples:
EXAMPLE 1
Calcipotriol (2.5 g) was dissolved in ethyl acetate (80 ml) at 50°-80° C. and filtered. The solution was saturated with water, and the product precipitated upon voluntary cooling to room temperature. The resulting slurry was cooled to 0°-10° C. and filtered. The filtered product was dried in vacuo to give calcipotriol, hydrate (2.35 g).
IR spectroscopy KBr technique
Lines characteristic for the hydrate are 1455 (m), 1442 (m), 1330 (w), 1290 (m), 1210 (m), 1085 (m), 907 (m), 895 (m) and 573 (w) cm−1, respectively.
Solid state CPMAS1 CPMAS 13 C NMR The following resonances are characteristic for calcipotriol, hydrate: 147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2 and 1.9 ppm, respectively.
Differential Scanning Calorimetry (DSC)
On a Perkin Elmer DSC7 instrument using 20° C./min. and approx. 2 mg sample, the hydrate shows loss of water near 117° C. and a melting peak near 169.7° C.
EXAMPLE 2
Calcipotriol (22.7 g) was dissolved in methanol (200-250 ml), filtered and concentrated in vacuo to a residue which was dissolved in ethyl acetate (200-250 ml) at 50°-80° C. and water (2 ml) was added. The resulting solution was seeded with calcipotriol, hydrate, and the product precipitated upon voluntary cooling to room temperature. Hexane (100 ml) was added from a dropping funnel, the resulting slurry was cooled to 0°-10° C. and filtered.
The filtered product was washed with a 1:1 mixture of ethyl acetate and hexane (200 ml) and dried in vacuo to give calcipotriol, hydrate (19.7 g), shown to be identical with the product described in Example 1.
EXAMPLE 3
Calcipotriol (120 mg) was dissolved in acetone (2 ml) and water (1.5-3 ml) was added. The product crystallized spontaneously and the resulting slurry was cooled to 0°-10° C. and filtered. The filtered product was dried in vacuo to yield calcipotriol, hydrate (100 mg), shown to be identical with the product of Example 1.
EXAMPLE 4
  • Cream 50 μg/g
  • Calcipotriol, hydrate . . . 50 mg
  • Cetomacrogol 1000 . . . 30 g
  • Cetostearylalcohol . . . 60 g
  • Chloroallylhexaminium chloride . . . 0.5 g
  • Propyleneglycol . . . 30 g
  • Disodiumhydrogenphosphate . . . 2 g
  • Liquid paraffin . . . 50 g
  • White soft paraffin . . . 170 g
  • Purified water . . . up to 1000 g
Melt cetomacrogol 1000, cetostearylalcohol, liquid paraffin and white soft paraffin at 75° C. Dissolve propylene glycol in water at 75° C. and mix the solution with the fatty phase. Homogenize the emulsion and cool to 30° C. Mill calcipotriol, hydrate in part of the aqueous phase to a particle size predominantly below 10 μm and suspend in an aqueous solution of disodiumhydrogenphosphate and chloroallylhexaminiumchloride. Add the suspension to the emulsion and fill the cream in tubes.
EXAMPLE 5
  • Gel 50 μg/g
  • Calcipotriol, hydrate . . . 52.2 mg (corresponding to 50 mg anhydrous)
  • Carbomer . . . 7 g
  • Cetomacrogol 1000 . . . 1 g
  • Diazolidinyl urea . . . 2 g
  • Dichlorobenzyl alcohol . . . 1 g
  • Disodium edetate . . . 0.5 g
  • Sodium hydroxide . . . 3.7 g
  • Propylene glycol . . . 30 g
  • Purified water . . . up to 1000 g
Dissolve cetomacrogol, diazolidinyl urea, dichlorobenzyl alcohol, disodium edetate and propylene glycol in water. Add carbomer and homogenize by high speed. Add during agitation sodium hydroxide dissolved in part of the water. Mill the calcipotriol, hydrate in a bottle of water with glass beads until a particle size below 10 μm has been obtained. Add the calcipotriol, hydrate suspension to the gel and mix for 30 minutes. Fill the gel into collapsible tubes.

Claims (19)

1. Calcipotriol monohydrate characterized by its storage stability at 40° C. after 12 months, its ready wettability and its suitability for wet ball milling characteristics .
2. Pharmaceutical composition containing the compound calcipotriol monohydrate of claim 1.
3. Pharmaceutical composition according to claim 2 which is a cream.
4. Pharmaceutical composition according to claim 2 which is a gel.
5. Pharmaceutical composition comprising calcipotriol monohydrate according to any one of claim 4 claims 2-4 and a pharmaceutically acceptable vehicle, with a content of the active component of calcipotriol monohydrate being 1-100 μg/g of the composition.
6. The method of preparing calcipotriol monohydrate which comprises dissolving calcipotriol in organic solvent and then adding water to the resulting solution to precipitate the hydrate, said hydrate being characterized by its storage stability at 40° C., its ready wettability and its suitability for wet ball milling characteristics .
7. In the preparation of a gel formulation which involves wet ball milling a calcipotriol component and adding the wet milled calcipotriol component to a gel base, the improvement which comprises wet milling calcipotriol hydrate as said component and using this wet milled hydrate for addition to said gel base, said hydrate being characterized by its storage stability at 40° C. after 12 months, its ready wettability and its suitability for wet ball milling characteristics .
8. Calcipotriol monohydrate according to claim 1, wherein said monohydrate exhibits an infrared spectrum which comprises the following characteristic lines based on the potassium bromide technique:
1455 (m), 1442 (m), 1330 (w), 1290 (m), 1210 (m), 1085 (m), 907 (m), 895 (m) and 573 (w) cm −1 , respectively.
9. Calcipotriol monohydrate according to claim 1 or 8, wherein said monohydrate exhibits a solid state CPMAS 13 C NMR spectrum which comprises the following resonances:
147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2 and 1.9 ppm, respectively.
10. A pharmaceutical composition according to claim 2, wherein said monohydrate exhibits an infrared spectrum which comprises the following characteristic lines based on the potassium bromide technique:
1455 (m), 1442 (m), 1330 (w), 1290 (m), 1210 (m), 1085 (m), 907 (m), 895 (m) and 573 (w) cm −1 , respectively.
11. A pharmaceutical composition according to claim 2 or 10, wherein said monohydrate exhibits a solid state CPMAS 13 C NMR spectrum which comprises the following resonances:
147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2 and 1.9 ppm, respectively.
12. Pharmaceutical composition according to claim 2 which is an ointment.
13. Pharmaceutical composition according to claim 2 which is a lotion.
14. Pharmaceutical composition according to claim 2 which is a solution.
15. Pharmaceutical composition according to claim 2 which is a suspension.
16. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 12 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 μg/g of the composition.
17. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 13 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 μg/g of the composition.
18. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 14 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 μg/g of the composition.
19. Pharmaceutical composition comprising calcipotriol monohydrate according to claim 15 and a pharmaceutically acceptable vehicle, with a content of the calcipotriol monohydrate being 1-100 μg/g of the composition.
US10/986,575 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue Expired - Lifetime USRE39706E1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939300763A GB9300763D0 (en) 1993-01-15 1993-01-15 Chemical compound
PCT/DK1994/000011 WO1994015912A1 (en) 1993-01-15 1994-01-07 New crystalline form of a vitamin d analogue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/491,892 Reissue US5763426A (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue

Publications (1)

Publication Number Publication Date
USRE39706E1 true USRE39706E1 (en) 2007-06-26

Family

ID=10728784

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/491,892 Ceased US5763426A (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue
US10/986,575 Expired - Lifetime USRE39706E1 (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/491,892 Ceased US5763426A (en) 1993-01-15 1993-01-15 Crystalline form of a vitamin D analogue

Country Status (17)

Country Link
US (2) US5763426A (en)
EP (1) EP0679154B1 (en)
JP (1) JP3729847B2 (en)
KR (1) KR100309751B1 (en)
CN (1) CN1040746C (en)
AT (1) ATE159717T1 (en)
AU (1) AU663249B2 (en)
CA (1) CA2151730C (en)
DE (1) DE69406529T2 (en)
DK (1) DK0679154T3 (en)
ES (1) ES2111287T3 (en)
FI (1) FI108638B (en)
GB (1) GB9300763D0 (en)
GR (1) GR3025668T3 (en)
NZ (1) NZ259679A (en)
RU (1) RU2128646C1 (en)
WO (1) WO1994015912A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition
US20100056644A1 (en) * 2006-11-29 2010-03-04 Nilendu Sen Pharmaceutical compositions containing anhydrous calcipotriene
US20100093676A1 (en) * 2007-03-15 2010-04-15 Wheeler Derek A Polyaphron topical composition with vitamin d
US20110014135A1 (en) * 2005-06-01 2011-01-20 Stiefel Research Australia Pty Ltd Vitamin formulation
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20130023501A1 (en) * 2009-12-22 2013-01-24 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US9549896B2 (en) 2007-06-26 2017-01-24 Drug Delivery Solutions Limited Bioerodible patch comprising a polyaphron dispersion
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710931B2 (en) * 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
ES2388425T5 (en) 1999-04-23 2020-02-12 Leo Pharma As Non-aqueous pharmaceutical composition for dermal use to treat psoriasis comprising a vitamin D, a corticosteroid and a solvent component
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
EP1458678A1 (en) * 2002-11-18 2004-09-22 Teva Pharmaceutical Industries Limited A crystallization method for purification of calcipotriene
MY139521A (en) 2004-03-18 2009-10-30 Leo Pharma As Stereoselective synthesis of vitamin d analogues
FR2871696B1 (en) * 2004-06-17 2006-11-10 Galderma Sa TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS
TWI318203B (en) * 2004-09-01 2009-12-11 Leo Pharma As Epimerization of allylic alcohols
AU2007212696B2 (en) * 2006-02-10 2011-05-19 Amgen Inc. Hydrate forms of AMG706
ES2406735T3 (en) 2006-03-17 2013-06-07 Leo Pharma A/S Isomerization of pharmaceutical intermediates
RU2452488C2 (en) * 2006-08-29 2012-06-10 Тева Фармасьютикал Индастриес Лтд. Pharmaceutical compositions containing vitamin d and corticosteroid
ES2272198B1 (en) * 2006-12-28 2008-06-01 Laboratorios Viñas S.A. PROCEDURE FOR OBTAINING CALCIPOTRIOL HYDRATE.
EP2300408B1 (en) * 2008-05-08 2016-04-13 United Therapeutics Corporation Process for the preparation of treprostinil monohydrate and its use for storage and shipping
US20120184514A1 (en) * 2009-07-01 2012-07-19 Vitamin Derivatives Inc. Vitamin d compounds and methods for preparing same
US9254296B2 (en) 2009-12-22 2016-02-09 Leo Pharma A/S Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
EP2515912A4 (en) * 2009-12-22 2013-12-25 Leo Pharma As Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
MX2012007229A (en) 2009-12-22 2012-07-30 Leo Pharma As Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants.
EP2515874B1 (en) * 2009-12-22 2014-08-20 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
KR101619077B1 (en) 2010-06-11 2016-05-10 레오 파마 에이/에스 A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
RU2602171C2 (en) 2011-03-24 2016-11-10 Лео Фарма А/С Composition containing lipid nanoparticles and corticosteroid or vitamin d derivative
JP5652723B2 (en) * 2012-08-17 2015-01-14 フォーモサ・ラボラトリーズ・インコーポレーテッド New crystal form of maxacalcitol
CN103724162A (en) * 2014-01-07 2014-04-16 成都医路康医学技术服务有限公司 Preparation method of medicine calcipotriol solvate for treating psoriasis
MA41818A (en) 2015-03-27 2018-01-30 Leo Pharma As MICRO-NEEDLE STAMP FOR ADMINISTRATION OF AN ACTIVE SUBSTANCE TO THE SKIN

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435325A (en) * 1979-05-23 1984-03-06 Roussel Uclaf 1α,25α-Dihydroxy-cholecalciferol and methods for the production thereof
JPS59104358A (en) 1982-12-03 1984-06-16 Teijin Ltd 1alpha,24-dihydroxycholecalciferol monohydrate and its preparation
WO1987000834A1 (en) * 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
US5292727A (en) * 1990-03-01 1994-03-08 Leo Pharmaceutical Products Ltd. Use of the treatment of acne

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435325A (en) * 1979-05-23 1984-03-06 Roussel Uclaf 1α,25α-Dihydroxy-cholecalciferol and methods for the production thereof
JPS59104358A (en) 1982-12-03 1984-06-16 Teijin Ltd 1alpha,24-dihydroxycholecalciferol monohydrate and its preparation
WO1987000834A1 (en) * 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
US4866048A (en) * 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5292727A (en) * 1990-03-01 1994-03-08 Leo Pharmaceutical Products Ltd. Use of the treatment of acne

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bagot et al., "Immunosuppressive effects of 1,25-dihydroxyvitamin D3 analog (Calcipotriol) on epidermal cells". Chemical Abstracts, vol. 119, No. 5, Aug. 2, 1993, Abstract No. 41719, p. 182, col. 1, see abstract and Proc. Workshop Vitamin D (8th) 1991, pp. 518-519. *
Braeutigam et al., "Effects of calcipotriol (MC903) and calcitriol after topical application on the skin of hairless rats. Much lower effect of calcipotriol on systemic calcium homeostasis". Chemical Abstracts vol. 117, No. 21, Nov. 23, 1992, abstract #205159, p. 93, col. 1, see abstract & Skin Pharmacol. vol. 5, No. 2, 1992, pp. 87-92. *
Kragblle et al., "Vitamin D analogs in the treatment of psoriasis". Chemical Abstracts, vol. 116, No. 25, Jun. 22, 1992, abstract No. 248622, p. 90, col. 1, see abstract & J. Cell. Biochem. vol. 49, No. 1, 1992, pp. 46-52. *
Larsen et al., "Structure and absolute configuration of a monohydrate of calcipotriol (1.alpha.,3,5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol", Acta Crystallographica, Section C, Crystal Structure Communications, vol. 49, No. 3, 1993, pp. 618-621, see the whole document. *
Thavarajah et al. "1,25(OH)2D3 and Calcipotriol (MC903) have similar effects on the induction of osteoclast-like cell formation in human bone marrow cultures". Biochemical and Biophysical Research Communications, vol. 171, No. 3, Sep. 28, 1990, pp. 1056-1063. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20110014135A1 (en) * 2005-06-01 2011-01-20 Stiefel Research Australia Pty Ltd Vitamin formulation
US8298515B2 (en) 2005-06-01 2012-10-30 Stiefel Research Australia Pty Ltd. Vitamin formulation
US8629128B2 (en) 2005-06-01 2014-01-14 Stiefel West Coast, Llc Vitamin formulation
US20100056644A1 (en) * 2006-11-29 2010-03-04 Nilendu Sen Pharmaceutical compositions containing anhydrous calcipotriene
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
US20100093676A1 (en) * 2007-03-15 2010-04-15 Wheeler Derek A Polyaphron topical composition with vitamin d
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition
US11065195B2 (en) 2007-03-15 2021-07-20 MC2 Therapeutics Limited Topical composition
US9549896B2 (en) 2007-06-26 2017-01-24 Drug Delivery Solutions Limited Bioerodible patch comprising a polyaphron dispersion
US20130023501A1 (en) * 2009-12-22 2013-01-24 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US10154959B1 (en) 2011-03-14 2018-12-18 Drug Delivery Solutions Limited Ophthalmic composition containing a polyaphron dispersion
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition

Also Published As

Publication number Publication date
FI108638B (en) 2002-02-28
AU663249B2 (en) 1995-09-28
CA2151730C (en) 2005-01-04
EP0679154B1 (en) 1997-10-29
DK0679154T3 (en) 1998-03-30
WO1994015912A1 (en) 1994-07-21
CN1115979A (en) 1996-01-31
FI952797A0 (en) 1995-06-07
KR100309751B1 (en) 2002-11-08
RU95116650A (en) 1997-06-10
KR950704249A (en) 1995-11-17
ATE159717T1 (en) 1997-11-15
NZ259679A (en) 1996-11-26
DE69406529T2 (en) 1998-05-28
RU2128646C1 (en) 1999-04-10
ES2111287T3 (en) 1998-03-01
CN1040746C (en) 1998-11-18
JPH08505612A (en) 1996-06-18
GR3025668T3 (en) 1998-03-31
FI952797A (en) 1995-06-07
EP0679154A1 (en) 1995-11-02
CA2151730A1 (en) 1994-07-21
GB9300763D0 (en) 1993-03-03
JP3729847B2 (en) 2005-12-21
AU5857394A (en) 1994-08-15
DE69406529D1 (en) 1997-12-04
US5763426A (en) 1998-06-09

Similar Documents

Publication Publication Date Title
USRE39706E1 (en) Crystalline form of a vitamin D analogue
US3930005A (en) Antiinflammatory agents and their use
JPH02191255A (en) Preparation of stable modification of
PT2503005E (en) Cortexolone-17alpha-propionate in hydrate crystalline form iv
TWI250158B (en) Crystal modification of lipoic acid
US2736681A (en) Chemical compounds
GB2107715A (en) Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
US4391755A (en) Steroid monohydrates, formulations containing same and method
US4447426A (en) Steroid monohydrates, formulations containing same and method
AU1178300A (en) Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-N- (pentylsulfonyl)-3H-benzimidazole-5-carboxamide
US4435325A (en) 1α,25α-Dihydroxy-cholecalciferol and methods for the production thereof
US4534911A (en) Method for the preparation of p-butoxyphenylacetyl-hydroxamic acid in the finely divided state and a composition containing this acid
JP2006160766A (en) CRYSTAL OF (±)2-(DIMETHYLAMINO)-1-{[O-(m-METHOXYPHENETHYL)PHENOXY]METHYL}ETHYL HYDROGEN SUCCINATE HYDROCHLORIDE
CA1127655A (en) N-benzoyl-retinylamines, their preparation and pharmaceutical formulations containing these compounds
JP2006160764A (en) CRYSTAL OF (±)2-(DIMETHYLAMINO)-1-{[O-(m-METHOXYPHENETHYL)PHENOXY]METHYL}ETHYL HYDROGEN SUCCINATE HYDROCHLORIDE
JP2677906B2 (en) Method for preparing physically stable crystalline .alpha.-modification of para-aminobenzenesulfanilamide
EP1070083B1 (en) Crystalline forms of 1s- [1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9- [[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino [1, 2-a][ 1,2] diazepine-1-carboxamide
WO2016084950A1 (en) Pharmaceutical composition
HU210879A9 (en) Pharmaceutical agents
US3857941A (en) Pharmaceutical compositions and use of prednisolone 17-benzoate
FR2757543A1 (en) PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED
EP0056465B1 (en) Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them
EP0056466A2 (en) Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them
CN114213485A (en) Preparation method of nicotinamide mononucleotide crystal
JPH09291073A (en) Vitamin d derivative of crystal form

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12